Anticoagulation and antiplatelet management in gastrointestinal endoscopy: A review of current evidence

Table 21 Endoscopic mucosal resection

Ref.	Year	Country	Study design	n	Polyp morphology	Procedure	Medication	Relative risk
Ono et al[113]	2019	Japan	Retrospective	1734	Size: Median size 8.5-9.5 ± 5 mm	EMR	Aspirin (continuation or ceased 3 d before)	Incidence of PPB per polyp resection 1.35% (P = 0.81) on antiplatelet therapy (study limited by not differentiating between aspirin vs thienopyridine)
So et al[50]	2019	South Korea	Retrospective	399	Size: Mean lesion size 34 mm	EMR	Aspirin (ceased day of procedure or 0-4 d before or ceased 5-7 d before or ceased 8-14 d before procedure)	Incidence of PBB 8.2% (either aspirin or thienopyridine monotherapy)
Albéniz et al[114]	2020	Spain	Prospective	1034	Size: ≥ 20 mm (mean size 30.5 mm)	EMR	Aspirin (cessation dependent on comorbidities)	Study expressed risk of PPB on antiplatelet monotherapy as OR: 2.51, 95%CI: 0.99-6.34, P < 0.001 (either aspirin or thienopyridine monotherapy)

OR: Odds ratio; EMR: Endoscopic mucosal resection; PPB: Post-procedural bleeding.